Compare AstraZeneca plc (AZN) vs Direxion Daily Semiconductor Bull 3X Shares (SOXL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
AstraZeneca plc vs Direxion Daily Semiconductor Bull 3X Shares — how do they compare? AstraZeneca plc trades at $168.99 (market cap $253.13B), while Direxion Daily Semiconductor Bull 3X Shares trades at $153.45. The key difference: AstraZeneca plc pays a 1.92% dividend while Direxion Daily Semiconductor Bull 3X Shares pays none. Which is the better fit depends on your goals.
| AZN | SOXL | |
|---|---|---|
Market Cap | $253.13B | — |
Sector | Health | Leveraged / Inverse |
52-Week High | $209.48 | $300.77 |
52-Week Low | $137.44 | $23.99 |
Enterprise Value | $279.37B | — |
Dividend Yield | 1.92% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AstraZeneca (AZN) trades at $169.47, down 1.25% amid recent volatility following a Phase III trial failure for Wainua. The stock shows bearish technical signals with key support at $168 and resistance at $170. Fundamentally, the company reported strong 2025 results with revenue of $58.74B and net income of $10.23B, though a recent $1.5B licensing deal for a lung cancer drug highlights ongoing pipeline investments. Analyst sentiment is mixed with 47.5% buy ratings but recent downgrades from firms like HSBC citing trial setbacks.
The outlook balances robust financials against pipeline execution risks. Revenue growth and high margins support valuation, but the Wainua failure raises concerns about future catalysts. Investors should weigh the company's strong cash flow and market position against clinical trial volatility and potential legal investigations. Near-term price action may hinge on Q2 2026 earnings due July 27, 2026.
SOXL, a 3x leveraged semiconductor ETF, trades at $165.37, down 13.99% in 24 hours amid sector-wide volatility. Technical indicators show a bearish trend with support at $159 and resistance at $168. Recent news highlights sharp declines driven by SK Hynix's expansion and AI stock sell-offs, exposing the fund's sensitivity to leverage decay and chip sector swings.
The outlook remains high-risk due to leveraged structure and semiconductor cyclicality. Near-term pressure from oversupply concerns and hedge fund selling suggests caution, though dips may attract speculative buys. Key risks include volatility decay and broader tech sentiment shifts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AstraZeneca plc
A merger between Astra of Sweden and Zeneca Group of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across several major therapeutic classes, including gastrointestinal, diabetes, cardiovascular, respiratory, cancer, and immunology. The majority of sales come from international markets with the United States representing close to one third of its sales.
Read more on AZN →About Direxion Daily Semiconductor Bull 3X Shares
SOXL is a leveraged ETF that seeks daily investment results corresponding to 300% of the daily performance of the ICE Semiconductor Index. It is designed as a tactical tool for experienced traders to take a bullish (long) position on the semiconductor sector. Due to the effects of compounding and leverage, the ETF is intended to be held for a single day and is not suitable for long-term investment.
Read more on SOXL →
